The new indication for Daiichi Sankyo's injection of trastuzumab in China has been approved for breakthrough therapy, for use in adjuvant treatment of breast cancer.

On February 12th, Takeda Pharmaceuticals announced that the injection of trastuzumab deruxtecan has been approved by the China National Medical Products Administration Center for Drug Evaluation for inclusion in the breakthrough therapy drug program. It is used for the treatment of HER2-positive adult breast cancer patients who still have residual invasive lesions after receiving anti-HER2 neoadjuvant therapy. Trastuzumab deruxtecan is a HER2-targeted antibody-drug conjugate developed by Takeda Pharmaceuticals and jointly developed with AstraZeneca.